Clinical Trial Update: Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update on selumetinib and MK-2206 or mFOLFOX for metastatic pancreatic cancer; the study has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Acinar Cell Carcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FLUOROURACIL (Fluorouracil)
• MK-2206 (MK-2206)
• OXALIPLATIN (Oxaliplatin)
• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-09